menu

Getting to the Root of CKD-Associated Pruritus: Questions From the Field

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Getting to the Root of CKD-Associated Pruritus: Questions From the Field

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    How can you optimize the management of your patients with CKD-associated pruritus? Our esteemed experts, Drs. Joel Topf and James Burton, address clinical questions directly from the field and provide valuable insights to enhance your treatment strategies and improve patient outcomes. Your patients with itch will thank you for tuning in!

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Joel Topf, MD
    Clinical Assistant Professor
    Oakland University
    William Beaumont School of Medicine
    Rochester, MI

    Dr. Topf has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Ownership Interest: AstraZeneca, Cara Therapeutics, OMIC, PROK, SERA, WBA
    Consulting Fees: AstraZeneca, Bayer, Cara Therapeutics, GSK, CSL Vifor

    Faculty:
    James Burton, DM, FRCP
    Professor of Renal Medicine
    University Of Leicester
    Leicester, United Kingdom

    Dr. Burton has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: A. Menarini, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Diaverum

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard J. Green, MS, MBA, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the limitations of current therapies used for managing patients with chronic kidney disease-associated pruritus (CKD-aP)
    • Utilize patient-reported outcomes to tailor treatment strategies to individual patient needs
    • Select the appropriate therapy for patients with moderate to severe CKD-aP
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, dermatologists, Nephrology nurses and Dialysis nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    How can you optimize the management of your patients with CKD-associated pruritus? Our esteemed experts, Drs. Joel Topf and James Burton, address clinical questions directly from the field and provide valuable insights to enhance your treatment strategies and improve patient outcomes. Your patients with itch will thank you for tuning in!

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Joel Topf, MD
    Clinical Assistant Professor
    Oakland University
    William Beaumont School of Medicine
    Rochester, MI

    Dr. Topf has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Ownership Interest: AstraZeneca, Cara Therapeutics, OMIC, PROK, SERA, WBA
    Consulting Fees: AstraZeneca, Bayer, Cara Therapeutics, GSK, CSL Vifor

    Faculty:
    James Burton, DM, FRCP
    Professor of Renal Medicine
    University Of Leicester
    Leicester, United Kingdom

    Dr. Burton has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: A. Menarini, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Diaverum

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard J. Green, MS, MBA, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the limitations of current therapies used for managing patients with chronic kidney disease-associated pruritus (CKD-aP)
    • Utilize patient-reported outcomes to tailor treatment strategies to individual patient needs
    • Select the appropriate therapy for patients with moderate to severe CKD-aP
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, dermatologists, Nephrology nurses and Dialysis nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 May 2024